Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business Update
Ampio Pharmaceuticals (AMPE) will host a conference call on August 4, 2021, at 4:30 pm EDT to discuss its financial results for Q2 2021 and provide a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ampio Pharmaceuticals (AMPE) will host a conference call on August 4, 2021, at 4:30 pm EDT to discuss its financial results for Q2 2021 and provide a corporate update. The call will be accessible domestically at 888-506-0062 and internationally at 973-528-0011, using conference ID 469825. Investors can also listen via the webcast available on Ampio's website. The company is focused on immunology-based therapies for inflammatory conditions, with its lead product, Ampion, backed by an extensive patent portfolio.
Positive
- Ampio's lead drug, Ampion, is supported by a strong patent portfolio with protection until 2037.
- Ampion is eligible for 12-year FDA market exclusivity upon approval.
Negative
- None.
Details
News Market Reaction – AMPE
The recorded move for AMPE in the trading session of this news was -5.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ENGLEWOOD, Colo., July 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended June 30, 2021, and provide a corporate business update on Wednesday, August 4, 2021, at 4:30 pm EDT/ 2:30 pm MT.
Conference Call & Webcast: | |
Wednesday, August 4, 2021, 4:30 pm EDT / 2:30 pm MT | |
Domestic: | 888-506-0062 - Conference ID# 469825 |
International: | 973-528-0011 - Conference ID# 469825 |
Webcast Link: | |
The conference call will also be available from the Investor Relations section of the Company's website at www.ampiopharma.com and will be archived there shortly after the live event.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact
Katie Kennedy
katiek@gregoryfca.com
610-731-1045
View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-report-fiscal-2021-second-quarter-financial-results-and-provide-corporate-business-update-301328721.html
SOURCE Ampio Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.